Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Tenaya Therapeutics, Inc. (TNYA)

$0.78 +0.25% NASDAQ: TNYA · 15-min delayed
  • SOUTH SAN FRANCISCO, California
  • Public · NASDAQ: TNYA
  • 70 employees
$158.0MMarket cap
$225.0KRevenue · FY2026
-$90.6MNet income
70Employees
TNYANASDAQ
2021IPO

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2026
$225.0K
Net income
-$90.6M
Total assets
$146.9M
Market cap
$158.0M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$93.3M
Operating income
-$93.3M
Income tax
$0
Net income
-$90.6M
EPS (basic)
$-0.59
EPS (diluted)
$-0.59

Balance sheet

Total assets
$146.9M
Current assets
$105.6M
Total liabilities
$23.7M
Current liabilities
$15.4M
Shareholders’ equity
$123.3M

Cash flow

Operating cash flow
-$68.3M
Investing cash flow
$56.1M
Financing cash flow
$108.4M
Net cash flow
$96.2M

Statements via Polygon.io (SEC filings)

NASDAQ: TNYA
$0.78 +0.25%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.55 $2.10

52-week range

Market cap
$158.0M
EPS (diluted)
$-0.59
Shares outstanding
202.6M
Open
Day range
Prev close
Volume
IPO date
Jul 30, 2021

Tenaya Therapeutics, Inc. (TNYA) Stock Price

  • Reported a net loss of $90.6M in FY2026.
  • Trading 63% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Tenaya Therapeutics, Inc..

Write a review
Newsroom

News about Tenaya Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Tenaya Therapeutics, Inc.: frequently asked questions

Is Tenaya Therapeutics, Inc. an American company?

Tenaya Therapeutics, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Tenaya Therapeutics, Inc. headquartered?

Tenaya Therapeutics, Inc. is headquartered in South San Francisco, California, United States.

Is Tenaya Therapeutics, Inc. publicly traded?

Yes — Tenaya Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol TNYA on the NASDAQ.

What does Tenaya Therapeutics, Inc. do?

Tenaya Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →